Interestingly, it was observed in the absence of intact type 1 IFN signaling, MIP immunotherapy loses its anti-tumor potential including i) suppression of CCL22 expression on tumor infiltrating DCs, ii) reduced migration of Tregs into the TME and iii) restoration of proliferation/effector function of intratumoral CD8+ T cells. The gene discussed is CCL22; the disease is neoplasm.